Saralasin
Also known as: 1-Sar-8-Ala-angiotensin II, P-113, Sar-1, Ala-8 Angiotensin II, Saralasin acetate, Saralasine, Sarcosine‑angiotensin II
Source Saralasin at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Synthetic octapeptide analog of angiotensin II (Sar-Arg-Val-Tyr-Ile-His-Pro-Phe) used mainly in experimental and diagnostic settings to evaluate renin‑angiotensin system activity.
Mechanism of Action
Partial agonist/competitive antagonist at the angiotensin II type 1 (AT1) receptor, inhibiting vasoconstrictive effects of endogenous angiotensin II.
Routes of Administration
Goals & Uses
- Research tool for RAS characterizationResearchHigh
- Antihypertensive effect in high-renin statesCardiovascularModerate
- Diagnosis of renin-dependent hypertensionDiagnosticModerate
- Angiotensin receptor blockadeDiagnosticModerate
Contraindications
- Low-renin hypertension or normal renin statesCardiovascularHigh
- PregnancyPopulationHighPotential fetal risk or insufficient safety data
- Sodium depletionMetabolicModerate
- Severe hypotensionCardiovascularHigh
Adverse Effects
- HypotensionCardiovascularCommonLow blood pressure
- FlushingVascularUncommonWarmth and redness of the skin
- TachycardiaCardiovascularUncommonAbnormally fast heart rate
- NauseaGastrointestinalUncommonFeeling of sickness or urge to vomit
- Hypertension (paradoxical)CardiovascularCommon
Drug Interactions
- Other vasodilators (e.g., nitroglycerin)Moderate
- ACE inhibitorsModerate
- DiureticsModerateMay worsen dehydration or electrolyte imbalance
Population Constraints
- Pediatric patientsAgeRelative
- Patients with normal or low renin activityCardiovascularAbsolute
- Pregnant womenReproductiveRelative
Regulatory Status
- European UnionUnapprovedNo marketing authorization in the European Union.
- United StatesUnapprovedInvestigational peptide; not FDA‑approved.
- United KingdomUnapprovedNot licensed for clinical use.
Not approved for therapeutic use in any jurisdiction; employed in research protocols and occasional diagnostic challenge tests.
Evidence & Sources
No sources recorded yet.
Frequently Asked Questions
What is Saralasin?
Synthetic octapeptide analog of angiotensin II (Sar-Arg-Val-Tyr-Ile-His-Pro-Phe) used mainly in experimental and diagnostic settings to evaluate renin‑angiotensin system activity.
What is Saralasin used for?
Saralasin is educationally associated with: Research tool for RAS characterization, Antihypertensive effect in high-renin states, Diagnosis of renin-dependent hypertension, Angiotensin receptor blockade. Educational only — not medical advice.
How is Saralasin administered?
Recorded routes of administration: Intravenous.
What are the potential side effects of Saralasin?
Reported adverse effects include: Hypotension, Flushing, Tachycardia, Nausea, Hypertension (paradoxical). This list is not exhaustive — consult a qualified clinician.
Who should avoid Saralasin?
Recorded contraindications: Low-renin hypertension or normal renin states, Pregnancy, Sodium depletion, Severe hypotension. Consult a qualified clinician before use.